An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition
- 20 April 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 16 (5), 457-468
- https://doi.org/10.1038/ncb2953
Abstract
Tumour cells, with stem-like properties, are highly aggressive and often show drug resistance. Here, we reveal that integrin αvβ3 serves as a marker of breast, lung and pancreatic carcinomas with stem-like properties that are highly resistant to receptor tyrosine kinase inhibitors such as erlotinib. This was observed in vitro and in mice bearing patient-derived tumour xenografts or in clinical specimens from lung cancer patients who had progressed on erlotinib. Mechanistically, αvβ3, in the unliganded state, recruits KRAS and RalB to the tumour cell plasma membrane, leading to the activation of TBK1 and NF-κB. In fact, αvβ3 expression and the resulting KRAS–RalB–NF-κB pathway were both necessary and sufficient for tumour initiation, anchorage independence, self-renewal and erlotinib resistance. Pharmacological targeting of this pathway with bortezomib reversed both tumour stemness and erlotinib resistance. These findings not only identify αvβ3 as a marker/driver of carcinoma stemness but also reveal a therapeutic strategy to sensitize such tumours to RTK inhibition.Keywords
This publication has 61 references indexed in Scilit:
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerNature Genetics, 2012
- A MEK-independent role for CRAF in mitosis and tumor progressionNature Medicine, 2011
- Ras trafficking, localization and compartmentalized signallingSeminars in Cell & Developmental Biology, 2011
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFRNature, 2011
- Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signallingNature Communications, 2011
- Understanding resistance to EGFR inhibitors—impact on future treatment strategiesNature Reviews Clinical Oncology, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progressionNature Medicine, 2009
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005